Summary: A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS.

Top Publications

  1. Aghaloo T, Felsenfeld A, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg. 2010;68:959-63 pubmed publisher
  2. Ramirez L, López Pintor R, Casañas E, Arriba L, Hernandez G. New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws. Oral Health Prev Dent. 2015;13:385-93 pubmed publisher
    ..aim of this paper was to review the current literature associating the non-bisphosphonate cancer-treatment drugs Denosumab, Bevacizumab and Sunitinib (used with or without bisphosphonate [BP]) with the presence of osteonecrosis of the ..
  3. Hiramatsu R, Ubara Y, Sawa N, Hoshino J, Hasegawa E, Kawada M, et al. Denosumab for low bone mass in hemodialysis patients: a noncontrolled trial. Am J Kidney Dis. 2015;66:175-7 pubmed publisher
  4. Okamatsu N, Sakai N, Karakawa A, Kouyama N, Sato Y, Inagaki K, et al. Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns. Biochem Biophys Res Commun. 2017;491:614-621 pubmed publisher
    b>Denosumab, a fully human monoclonal antibody that neutralizes receptor activator of nuclear factor-?B ligand (RANKL) and blocks osteoclast differentiation, has received approval in Japan for use as an anti-resorptive drug for ..
  5. Balke M. Denosumab treatment of giant cell tumour of bone. Lancet Oncol. 2013;14:801-2 pubmed publisher
  6. Aspenberg P. Denosumab and atypical femoral fractures. Acta Orthop. 2014;85:1 pubmed publisher
  7. Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab--a case report. Acta Orthop. 2014;85:6-7 pubmed publisher
  8. Alibhai S, Zukotynski K, Walker Dilks C, Emmenegger U, Finelli A, Morgan S, et al. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. Ann Intern Med. 2017;167:341-350 pubmed publisher
    ..Bone health is a significant concern in men with prostate cancer...
  9. Kane C, Hoskin P, Bennett M. Cancer induced bone pain. BMJ. 2015;350:h315 pubmed publisher

More Information


  1. Cating Cabral M, Clarke B. Denosumab and atypical femur fractures. Maturitas. 2013;76:1-2 pubmed publisher
  2. Drampalos E, Skarpas G, Barbounakis N, Michos I. Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop. 2014;85:3-5 pubmed publisher
  3. Sato F, Toi M. [Molecular targeted therapy and genomic evolution of breast cancer]. Nihon Rinsho. 2015;73:1364-72 pubmed
    ..In this article, latest knowledge regarding breast cancer genome, especially in terms of 'evolution', is summarized. ..
  4. Durden E, Pinto L, Lopez Gonzalez L, Juneau P, Barron R. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos. 2017;12:22 pubmed publisher
    ..raloxifene (daily), or zoledronic acid (annually) had significantly lower odds of persistence compared with denosumab (every 6 months)...
  5. Anagnostis P, Paschou S, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 2017;101:23-30 pubmed publisher
    Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal osteoporosis...
  6. van der Heijden L, van de Sande M, Hogendoorn P, Gelderblom H, Dijkstra P. Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report. Acta Orthop. 2015;86:393-5 pubmed publisher
  7. Miyazawa Y, Sekine Y, Syuto T, Nomura M, Koike H, Matsui H, et al. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab. Anticancer Res. 2017;37:3667-3671 pubmed
    ..Therefore, bone quality markers were evaluated retrospectively in PCa patients receiving ADT with or without denosumab. This study included 46 PCa patients. Twenty patients received denosumab...
  8. Qaseem A, Forciea M, McLean R, Denberg T. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017;166:818-839 pubmed publisher
    ..ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis...
  9. Khan A, Morrison A, Hanley D, Felsenberg D, McCauley L, O Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3-23 pubmed publisher
    ..ONJ is associated with oncology-dose parenteral antiresorptive therapy of bisphosphonates (BP) and denosumab (Dmab)...
  10. D Amico A. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol. 2014;32:362-4 pubmed publisher
  11. . Denosumab. Limited efficacy in fracture prevention, too many adverse effects. Prescrire Int. 2011;20:145-8 pubmed
    ..There are no drugs with demonstrated efficacy on the risk of fracture in castrated men with prostate cancer. Denosumab, a monoclonal antibody that inhibits a cytokine acting mainly on bone cells and lymphocytes, has been authorised ..
  12. Crandall C, Newberry S, Diamant A, Lim Y, Gellad W, Booth M, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014;161:711-23 pubmed publisher
    ..There is high-strength evidence that bisphosphonates, denosumab, and teriparatide reduce fractures compared with placebo, with relative risk reductions from 0.40 to 0...
  13. Graff J, Beer T. Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. Oncology (Williston Park). 2015;29:416-23 pubmed
    ..Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223...
  14. Steeg P. Perspective: The right trials. Nature. 2012;485:S58-9 pubmed publisher
  15. Anastasilakis A, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int. 2016;27:1929-30 pubmed publisher
  16. Logothetis C. Treatment of prostate cancer metastases: more than semantics. Lancet. 2012;379:4-6 pubmed publisher
  17. Buckley L, Guyatt G, Fink H, Cannon M, Grossman J, Hansen K, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69:1521-1537 pubmed publisher
    ..and harms of lifestyle modification and of calcium, vitamin D, bisphosphonate, raloxifene, teriparatide, and denosumab treatment in the general adult population receiving long-term GC treatment, as well as in special populations of ..
  18. Thomas D, Carriere P, Jacobs I. Safety of denosumab in giant-cell tumour of bone. Lancet Oncol. 2010;11:815 pubmed publisher
  19. Schröder J, Fietz T, Köhler A, Petersen V, Tesch H, Spring L, et al. Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study. Eur J Cancer. 2017;79:139-148 pubmed publisher
    ..In 2014-2015, 37% of the patients received the bisphosphonate zoledronic acid and 36% the antibody denosumab. Median duration of BTA therapy was 20 months (interquartile range 31...
  20. Body J, Gatta F, De Cock E, Tao S, Kritikou P, Wimberger P, et al. An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. Support Care Cancer. 2017;25:2823-2832 pubmed publisher
    b>Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase ..
  21. Ishiguro S, Ito K, Nakagawa S, Hataji O, Sudo A. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease. Arch Osteoporos. 2017;12:44 pubmed publisher
    ..Our data indicates that denosumab can also play a role in the treatment of osteoporosis in the steroid-taking population...
  22. Kato S. [Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor]. Nihon Rinsho. 2015;73:1398-402 pubmed
    ..In this chapter, the molecular target drug for the soft tissue sarcoma and the neuroendocrine tumor is reviewed. ..
  23. Niibe K, Ouchi T, Iwasaki R, Nakagawa T, Horie N. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J Prosthodont Res. 2015;59:3-5 pubmed publisher
  24. Fujimura T, Kambayashi Y, Furudate S, Asano M, Kakizaki A, Aiba S. Receptor Activator of NF-?B Ligand Promotes the Production of CCL17 from RANK+ M2 Macrophages. J Invest Dermatol. 2015;135:2884-2887 pubmed publisher
  25. Ji T, Yang Y, Wang Y, Sun K, Guo W. Combining of serial embolization and denosumab for large sacropelvic giant cell tumor: Case report of 3 cases. Medicine (Baltimore). 2017;96:e7799 pubmed publisher
    Both serial arterial embolization (SAE) and denosumab have been proved to be effective in treatment for giant cell tumor (GCT). There is potential synergic effect of combining two methods...